Month: November 2011

Bemis Company ( BMS ) reported third-quarter EPS of $0.56, a penny below the year-ago quarter and missing the Zacks Consensus Estimate by 2 cents. Rising raw materials prices have significantly impacted the company, putting downward pressure on its margins. Nearly 35% of its total revenues last year came from its business outside the United States. […]

With a strong financial position, we believe Neurocrine Biosciences ( NBIX ) is in an outstanding position to build shareholder value over the next several years. The company exited the third quarter 2011 with over $140 million in cash and investments, with the potential to earn several hundred million more as clinical development progresses. The company's dramatically improved financial position affords management the opportunity to push forward the development of internal pipeline candidates, including VMAT-2, as well as in-license new pre-phase 2 molecules within the company's core CNS focus […]

Healthstream, Inc. ( HSTM ) is trading in a class of its own, recently hitting a new 52-week high on another great quarter. With an average earnings surprise of 42% over the last four quarters and a bullish growth projection, this Zacks #1 Rank stock offers a healthy stream of momentum […]